Protagonist Therapeutics, Inc. Price Chart
Protagonist Therapeutics, Inc. PGF.SG Financial and Trading Overview
| Protagonist Therapeutics, Inc. stock price | 15.2 EUR |
| Previous Close | 15.2 EUR |
| Open | 15.2 EUR |
| Bid | 15.1 EUR x 0 |
| Ask | 15.6 EUR x 0 |
| Day's Range | 15 - 15.8 EUR |
| 52 Week Range | 10.8 - 42.8 EUR |
| Volume | 180 EUR |
| Avg. Volume | 179 EUR |
| Market Cap | 726.44M EUR |
| Beta (5Y Monthly) | 1.962676 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.46 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 44.25 EUR |
PGF.SG Valuation Measures
| Enterprise Value | 642.52M EUR |
| Trailing P/E | N/A |
| Forward P/E | -6.4957266 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 845.67914 |
| Price/Book (mrq) | 3.6173248 |
| Enterprise Value/Revenue | 747.987 |
| Enterprise Value/EBITDA | -4.424 |
Trading Information
Protagonist Therapeutics, Inc. Stock Price History
| Beta (5Y Monthly) | 1.962676 |
| 52-Week Change | -11.62% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 42.8 EUR |
| 52 Week Low | 10.8 EUR |
| 50-Day Moving Average | 31.01 EUR |
| 200-Day Moving Average | 30.82 EUR |
PGF.SG Share Statistics
| Avg. Volume (3 month) | 179 EUR |
| Avg. Daily Volume (10-Days) | 180 EUR |
| Shares Outstanding | 47.55M |
| Float | 45.05M |
| Short Ratio | N/A |
| % Held by Insiders | 1.67% |
| % Held by Institutions | 104.09% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | N/A |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -17029.45% |
| Gross Margin | 100.00% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -31.089% |
| Return on Equity (ttm) | -54.13% |
Income Statement
| Revenue (ttm) | 859K EUR |
| Revenue Per Share (ttm) | 0.02 EUR |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | 26.58M EUR |
| EBITDA | -145250000 EUR |
| Net Income Avi to Common (ttm) | -140188000 EUR |
| Diluted EPS (ttm) | -2.46 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 230.76M EUR |
| Total Cash Per Share (mrq) | 4.03 EUR |
| Total Debt (mrq) | 3.06M EUR |
| Total Debt/Equity (mrq) | 1.42 EUR |
| Current Ratio (mrq) | 10.148 |
| Book Value Per Share (mrq) | 4.202 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -104818000 EUR |
| Levered Free Cash Flow (ttm) | -52034876 EUR |
Profile of Protagonist Therapeutics, Inc.
| Country | Germany |
| State | CA |
| City | Newark |
| Address | 7707 Gateway Boulevard |
| ZIP | 94560-1160 |
| Phone | 510 474 0170 |
| Website | https://www.protagonist-inc.com |
| Industry | |
| Sector(s) | |
| Full Time Employees | 103 |
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of erythrocytosis, iron overload, and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that is in Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist, which is in Phase II clinical trials for inflammatory bowel disease. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Q&A For Protagonist Therapeutics, Inc. Stock
What is a current PGF.SG stock price?
Protagonist Therapeutics, Inc. PGF.SG stock price today per share is 15.2 EUR.
How to purchase Protagonist Therapeutics, Inc. stock?
You can buy PGF.SG shares on the Stuttgart exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Protagonist Therapeutics, Inc.?
The stock symbol or ticker of Protagonist Therapeutics, Inc. is PGF.SG.
How many shares does Protagonist Therapeutics, Inc. have in circulation?
The max supply of Protagonist Therapeutics, Inc. shares is 47.79M.
What is Protagonist Therapeutics, Inc. Price to Earnings Ratio (PE Ratio)?
Protagonist Therapeutics, Inc. PE Ratio is now.
What was Protagonist Therapeutics, Inc. earnings per share over the trailing 12 months (TTM)?
Protagonist Therapeutics, Inc. EPS is -2.46 EUR over the trailing 12 months.